Medicinal Products Prices

Dáil Éireann Debate, Tuesday - 20 November 2018

Tuesday, 20 November 2018

Questions (362)

Thomas P. Broughan

Question:

362. Deputy Thomas P. Broughan asked the Minister for Health further to Parliamentary Question Nos. 238 and 670 of 18 October 2018, the reason the rare diseases technology review committee does not have a direct input into the NCPE health technology assessment process; if the committee will be permitted to replicate to the Scottish PACE model to have a direct input into the pharmacoeconomic evaluation of orphan medicinal products; and if he will make a statement on the matter. [47768/18]

Written answers

Minister for Health

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.